Caprotec Touts Success of CCMS Technology in Drug Development Study with Roche

The company said that protein targets binding specifically to the drug in question showed activity in pathways commensurate with the drug candidate's phenotypic profile.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.